GlassScriptPhysician profile
Jacqueline K Beaver
NPI 1568577260
$8,395.60
in general payments reported to CMS, 2019-2025
27 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $1,477 · 2023: $1,823 · 2024: $1,788 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,094 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,094.10 |
| Education | $331.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,384.75 | 2021-2025 | |
| Janssen Biotech, INC. | $937.08 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $748.95 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $620.66 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $558.45 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $478.74 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $449.82 | 2022-2025 | Sotyktu |
| Amgen INC. | $355.18 | 2021-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $317.80 | 2022-2025 | Opzelura |
| Genzyme Corporation | $313.20 | 2021-2025 | |
| Ucb, INC. | $202.58 | 2021-2025 | Bimzelx, Cimzia |
| Sandoz INC. | $131.85 | 2023-2025 | Hyrimoz |
| Pfizer INC. | $127.94 | 2022-2025 | |
| Leo Pharma INC. | $119.47 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.73 | 2023-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $90.01 | 2023-2025 | Zoryve |
| Convatec INC. | $84.52 | 2025 | |
| Kerecis Limited | $77.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $69.50 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $54.63 | 2023 | Vtama |
| Smith+Nephew, INC. | $54.39 | 2021-2023 | Grafix Pl |
| Genentech USA, INC. | $34.97 | 2024 | Erivedge |
| Boston Scientific Corporation | $23.43 | 2021 | |
| Allergan, INC. | $18.94 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.62 | 2025 | Cabtreo |
| Almirall LLC | $18.59 | 2023 | Klisyri |
| Organon LLC | $6.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.